NCT06900595 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia